Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2009-09-03Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB) [Phase 3]
Phase 3 trial comparing fesoterodine with tolterodine evaluated efficacy and safety in overactive bladder. Results were posted following com…
-
CLINICAL_TRIALS trial_result · 2009-08-04Clinical Trial Update: Intravesical Instillation of Botulinum Toxin Type A to Patients With Urge Urinary Incontinence [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating intravesical instillation of botulinum toxin type A for urge urinary incontinence.
-
CLINICAL_TRIALS trial_result · 2009-07-07Clinical Trial Update: Microorganism in Overactive Bladder Patients [Phase 4]
Phase 4 clinical trial evaluating a microorganism therapy for overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2009-05-18Clinical Trial Update: Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms [Phase 2]
A Phase 2 dose-ranging trial comparing solabegron to placebo in women with overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2009-05-15Clinical Trial Update: Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder [Phase 4]
Phase 4 clinical trial update reporting urinary urgency outcomes after treatment with propiverine in patients with Overactive bladder.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2009-02-10Clinical Trial Update: A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients [Phase 3]
Phase 3 clinical trial assessing fesoterodine for treatment satisfaction and symptom improvement in overactive bladder; completed with resul…
-
CLINICAL_TRIALS trial_result · 2009-01-22Clinical Trial Update: Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP) [Phase 4]
Phase 4 clinical trial evaluating solifenacin for overactive bladder symptoms in patients who have undergone GreenLight PVP surgery.
-
CLINICAL_TRIALS trial_result · 2008-12-25Clinical Trial Update: A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031 [Phase 1]
This Phase 1 trial is a randomized, double-blind, placebo-controlled two-way crossover study to assess the safety and tolerability of a sing…
-
CLINICAL_TRIALS trial_result · 2008-11-24Clinical Trial Update: Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome [Phase 3]
Long-term open-label extension study for subjects completing a Phase 3 trial of fesoterodine for overactive bladder (Phase 3).
-
CLINICAL_TRIALS trial_result · 2008-11-24Clinical Trial Update: Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome [Phase 3]
Pfizer reports the completion of a long-term open-label extension study for fesoterodine (SP584) in subjects who completed the Phase 3 trial…
-
CLINICAL_TRIALS trial_result · 2008-11-21Clinical Trial Update: Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder [Phase 2]
Completed Phase 2 dose-escalation trial evaluating propiverine hydrochloride in children with overactive bladder.
-
CLINICAL_TRIALS trial_result · 2008-10-16Clinical Trial Update: Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase [Phase 2]
Phase 2 extension study assessing the safety and tolerability of sustained-release fesoterodine (SP668) in subjects with overactive bladder,…
-
CLINICAL_TRIALS trial_result · 2008-10-07Clinical Trial Update: A Two-Part Study to Determine: Best Medication Formulation and Food Effect [Phase 1]
Phase 1 two-part study by GlaxoSmithKline to determine the best medication formulation and food effect for an overactive bladder agent; the …
-
CLINICAL_TRIALS trial_result · 2008-06-17Clinical Trial Update: Programmable Timer in the Bladder Rehabilitation Treatment of OAB [NA]
A clinical trial update indicating the study on a programmable timer for bladder rehabilitation in overactive bladder and urinary incontinen…
-
CLINICAL_TRIALS trial_result · 2008-06-17Clinical Trial Update: Surface Nerve Stimulation Treatment for OAB in Children [NA]
A clinical trial evaluating surface nerve stimulation for pediatric overactive bladder and urinary incontinence has completed.
-
CLINICAL_TRIALS trial_result · 2008-06-04Clinical Trial Update: Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity
This clinical trial update reports the safety and efficacy of solifenacin in men with overactive bladder and detrusor underactivity; the stu…
-
CLINICAL_TRIALS trial_result · 2008-05-05Clinical Trial Update: A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome [Phase 3]
A multicenter Phase 3 trial evaluating fesoterodine sustained release for overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2008-04-10Clinical Trial Update: A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients [Phase 3]
A Phase 3 double-blind, head-to-head trial comparing solifenacin to tolterodine in overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2008-04-10Clinical Trial Update: Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome [Phase 3]
Phase 3 trial evaluating fesoterodine sustained release for overactive bladder has completed, assessing efficacy, tolerability, and safety.
-
CLINICAL_TRIALS trial_result · 2008-04-01Clinical Trial Update: Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity [Phase 2, Phase 3]
Clinical trial update indicating completion of a Phase 2/Phase 3 study evaluating topical estrogens and antimuscarinics for detrusor overact…
-
CLINICAL_TRIALS trial_result · 2008-03-31Clinical Trial Update: A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring [Phase 3]
Phase 3 study evaluating tolterodine extended-release versus propiverine for overactive bladder in Korean patients, assessed by ambulatory u…
-
CLINICAL_TRIALS trial_result · 2008-02-25Clinical Trial Update: Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity [Phase 2]
Phase 2 trial of AV608 for idiopathic detrusor overactivity (overactive bladder) evaluated safety and efficacy; the study was terminated.
-
CLINICAL_TRIALS trial_result · 2008-01-29Clinical Trial Update: Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence [Phase 3]
Phase 3 clinical trial of propiverine in children with non-neurogenic overactive bladder and urinary incontinence has completed.
-
CLINICAL_TRIALS trial_result · 2008-01-24Clinical Trial Update: Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder [Phase 4]
Phase 4 clinical trial sponsored by Novartis evaluated darifenacin with behavioral therapy for symptoms of overactive bladder and has comple…
-
CLINICAL_TRIALS trial_result · 2008-01-23Clinical Trial Update: A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. [Phase 3]
A Phase 3 clinical trial evaluating darifenacin for increasing warning time in patients with overactive bladder has completed.